-
Product Insights
New![]()
Net Present Value Model: CNS Pharmaceuticals Inc’s Berubicin hydrochloride
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Secondary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Secondary CNS Lymphoma Drug Details: Lisocabtagene maraleucel (Breyanzi) is a CD19-directed genetically...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Primary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Primary CNS Lymphoma Drug Details: Lisocabtagene maraleucel (Breyanzi) is a CD19-directed genetically...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Acalabrutinib Maleate in CNS Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Acalabrutinib maleate in CNS Lymphoma Drug Details: Acalabrutinib maleate (Calquence) is an anti-neoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Secondary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Secondary CNS Lymphoma Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio) a programmed death-ligand...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Satraplatin in Primary CNS Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Satraplatin in Primary CNS LymphomaDrug Details:Satraplatin is under development for the treatment of primary CNS lymphoma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zanubrutinib in Primary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanubrutinib in Primary CNS Lymphoma Drug Details: Zanubrutinib (Brukinsa) acts as an antineoplastic agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zanubrutinib in Secondary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanubrutinib in Secondary CNS Lymphoma Drug Details: Zanubrutinib (Brukinsa) acts as an antineoplastic agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tisagenlecleucel in Primary CNS Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tisagenlecleucel in Primary CNS LymphomaDrug Details:Tisagenlecleucel (Kymriah) is a CD19-directed genetically modified autologous of T cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Emfizatamab in Primary CNS Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Emfizatamab in Primary CNS LymphomaDrug Details:Emfizatamab (GNC-038) is under development for the treatment of recurrent or...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.